ペマフィブラート ワ シシツイジョウショウ オ トモナウ ヒアルコールセイ シボウセイカン シッカン カンジャ ノ カンキノウ ケンサ ト センイカ マーカー ノ アタイ オ ゲキテキ ニ カイゼン スル
Year: 2024
Type: dissertation
Abstract: Background Non-alcoholic fatty liver disease ( NA FLD) is a ch ronic liver disease related to metabolic syndrome, which can progress to liver cirrhosis.Standard medication has not been established.Pemafibrate is a selective peroxisome proliferatoractivated receptor (PPAR) α modulator.We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD.Methods We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27-81 years).They were all proven to have fatty liver through imaging and had little or no history of drinking (ethanol consumption of < 20 g/day for women and < 30 g/day for men).They were administered pemafibrate from October 2018 to June 2020.Results After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06).Serum high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels did not change.ALT was significantly decreased (-47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01).The values of serum GGT significantly decreased (-48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01).Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05).Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change.Conclusion Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD.
Author: 池田,傑
Institution: Tottori University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7146658983